Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China-Reference-Cited by-同舟云学术

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

Published:2016-12-27 Issue:6 Volume:8 Page:9996-10006
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Lu Shun¹,Ye Ming²,Ding Lieming³,Tan Fenlai³,Fu Jie⁴,Wu Bin⁴

Affiliation:

1. Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China

2. Department of Radiotherapy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

3. Betta Pharmaceuticals Co., Ltd., Hangzhou, China

4. Medical Decision and Economic Group, Department of Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Critical Examination of Modeling Approaches Used in Economic Evaluations of First-Line Treatments for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: A Systematic Literature Review;PharmacoEconomics;2024-03-15

2. Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China;Expert Review of Pharmacoeconomics & Outcomes Research;2023-11-07

3. Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma;Frontiers in Oncology;2023-10-31

4. A meta-analysis for the efficacy and safety of icotinib combined with radiotherapy in treating brain metastases of non-small cell lung cancer;Medicine;2023-09-08

5. Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost‐effectiveness analysis;Cancer Medicine;2023-09